Genomic technology could accelerate patient trials of new cancer drugs that are targeted to a tumor’s individual molecular profile.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
For the first time, researchers report that monkeys can use brain implants to control a left and a right arm.
A method for single-cell DNA analysis could provide a safer genetic screen for IVF.
Computer-controlled sedation could lighten the load for intensive-care staff and make the process safer for patients.
Dimension Therapeutics wants to develop a lifetime fix for hemophilia using gene therapy.
A startup will sift through “treasure troves” of data from failed trials to find abandoned Alzheimer’s drugs that might work for some patients.
The U.K. plans to sequence 100,000 National Health Service patients by 2017—in a bold push to be a genomic medicine leader.
Spark Therapeutics hopes to commercialize multiple gene-based treatments developed at the Children's Hospital of Philadelphia.
Biotech startup Greenlight Biosciences has a cell-free approach to microbial chemical production.
Study suggests how brain technology could one day tap into thoughts.